8-K: ANI Pharma Projects $1B+ Revenue, Driven by Rare Disease Growth

ANI Pharmaceuticals, Inc. announced strong preliminary 2025 financial results and robust 2026 guidance, projecting over $1 billion in total net revenues, primarily fueled by its Rare Disease business.

Summary

• Preliminary unaudited full year 2025 total net revenues are expected to be within or above the guidance range of $854 million to $873 million.
• Preliminary unaudited full year 2025 adjusted non-GAAP EBITDA is expected to be within or above the guidance range of $221 million to $228 million.
• Preliminary unaudited full year 2025 adjusted non-GAAP diluted EPS is expected to be within or above the guidance range of $7.37 to $7.64.
• Cortrophin Gel net revenues for full year 2025 reached approximately $347.8 million, a 76% year-over-year increase.
• ILUVIEN and YUTIQ combined net revenues for full year 2025 were approximately $74.9 million.
• Full year 2026 total net revenue guidance is set at $1,055 million to $1,115 million, representing 24% 28% year-over-year growth.
• Full year 2026 Cortrophin Gel net revenue guidance is $540 million to $575 million, indicating 55% 65% year-over-year growth.
• Full year 2026 adjusted non-GAAP EBITDA guidance is $275 million to $290 million, reflecting 24% 27% year-over-year growth.
• Full year 2026 adjusted non-GAAP diluted EPS guidance is $8.83 to $9.34, representing 20% 22% year-over-year growth.
• The Rare Disease business is projected to represent approximately 60% of total net revenues in 2026.
• The company plans a ~90-person expansion of its Rare Disease organization by mid-2026 to target acute gouty arthritis flares for Cortrophin Gel.
• As of December 31, 2025, the company had approximately $285 million in unrestricted cash and cash equivalents.

Sentiment

Score: 9

Explanation: The filing presents very strong preliminary 2025 results that met or exceeded guidance, coupled with highly optimistic and robust 2026 financial guidance. The strategic focus on the high-growth Rare Disease segment, particularly Cortrophin Gel, and planned organizational expansion indicate strong future prospects. The only minor caveats are the unaudited nature of preliminary results and standard forward-looking statement risks.

Positives

• Strong preliminary 2025 financial results exceeding or meeting previous guidance for total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS.
• Exceptional 76% year-over-year growth in Cortrophin Gel net revenues to $347.8 million in 2025.
• Robust 2026 financial guidance projecting over $1 billion in total net revenues ($1,055 million $1,115 million), a 24% 28% increase year-over-year.
• Significant projected growth for Cortrophin Gel in 2026, with net revenues expected to reach $540 million $575 million (55% 65% year-over-year growth).
• Rare Disease business is becoming the primary driver of growth, expected to account for approximately 60% of total revenues in 2026.
• Planned ~90-person expansion of the Rare Disease organization to capture the unique opportunity for Cortrophin Gel in acute gouty arthritis flares, deploying by mid-2026.
• Generics business outperformed in 2025 with >20% year-over-year topline growth and is expected to continue providing healthy cash generation.
• Strong cash position with approximately $285 million in unrestricted cash and cash equivalents as of December 31, 2025.
• ACTH market returned to double-digit growth in 2024 following the launch of Cortrophin Gel, with the market estimated to reach ~$992 million in 2025, up 45% year-over-year.
• Over 90% of revenues come from finished goods manufactured in the U.S., reducing reliance on foreign supply chains.

Negatives

• Preliminary financial results are unaudited and subject to change, which may be material.
• The independent registered public accounting firm has not audited or reviewed these preliminary results and does not express an opinion or provide assurance.
• Reliance on single-source third-party contract manufacturing supply for certain key products, including Cortrophin Gel and ILUVIEN, poses a risk of delays and disruptions.
• The company is not providing a reconciliation for forward-looking non-GAAP guidance due to insufficient information to accurately estimate all variables and adjustments without unreasonable effort.

Risks

• The ability of approved products, including Cortrophin Gel and ILUVIEN, to achieve commercialization at levels of market acceptance that will continue to allow for continued profitability.
• The ability to complete or achieve any, or all of the intended benefits of acquisitions and investments, such as the Alimera acquisition, in a timely manner or at all.
• The limitation of cash flow as a result of the indebtedness and liabilities incurred from the acquisition of Alimera.
• Risks that acquisitions and investments could disrupt the business and harm financial position and operating results.
• Delays and disruptions in production of approved products, increased costs, and potential loss of revenues if there is a need to change suppliers due to the limited number of suppliers for raw materials, active pharmaceutical ingredients, expedients, and other materials.
• Delays and disruptions in production of approved products as a result of reliance on single-source third-party contract manufacturing supply for certain key products, including Cortrophin Gel and ILUVIEN.
• Delays or failure in obtaining and maintaining approvals by the FDA of the products sold.
• Changes in policy or actions that may be taken by the FDA, United States Drug Enforcement Administration, and other regulatory agencies, including drug recalls, regulatory approvals, facility inspections, and potential enforcement actions.
• Risks related to importing raw materials and delays in delivery of raw materials and other ingredients and supplies necessary for the manufacture of products from both domestic and overseas sources due to supply chain disruptions or for any other reason, including increased costs due to tariffs.
• The ability of manufacturing partners to meet product demands and timelines.
• The impact of changes or fluctuations in exchange rates.
• The ability to develop, license or acquire, and commercialize new products.
• Obligations in agreements under which the company licenses, develops, or commercializes rights to products or technology from third parties and the ability to maintain such licenses.
• The level of competition faced and the legal, regulatory, and/or legislative strategies employed by competitors to prevent or delay competition from generic alternatives to branded products.
• The ability to protect intellectual property rights.
• The impact of legislative or regulatory reform on the pricing for pharmaceutical products.
• The impact of any litigation to which the company is, or may become, a party.
• The ability, and that of suppliers, development partners, and manufacturing partners, to comply with laws, regulations, and standards that govern or affect the pharmaceutical and biotechnology industries.
• The ability to maintain the services of key executives and other personnel.
• The potential impact of new U.S. tax legislation on the business.
• General business and economic conditions, such as inflationary pressures and geopolitical conditions.

Future Outlook

ANI Pharmaceuticals projects significant growth in 2026, with total net revenues expected to exceed $1 billion, driven primarily by its high-growth Rare Disease business, which is anticipated to represent approximately 60% of total revenues. Cortrophin Gel is forecasted to achieve substantial year-over-year growth of 55% to 65%, reaching $540 million to $575 million in net revenues. The company plans to expand its Rare Disease organization by mid-2026 with ~90 new personnel to capitalize on the acute gouty arthritis flares indication for Cortrophin Gel and advance a Phase 4 clinical trial. The Generics business is expected to continue generating strong cash flows, supporting investments in Rare Disease R&D and maintaining a cadence of 10 to 15 new product launches annually.

Management Comments

• "2025 was a pivotal year for ANI, as we drove significant growth for Cortrophin Gel and outperformed in our Generics business, enabling us to achieve at least 39% growth in total net revenues and at least 42% growth in adjusted non-GAAP EBITDA." Nikhil Lalwani, President and CEO.
• "We are entering 2026 in a position of strength and expect to generate over $1 billion in total net revenues this year, approximately 60% of which will be represented by our high-growth Rare Disease business." Nikhil Lalwani, President and CEO.
• "To accelerate our transformation into a leading Rare Disease company, we are focused on maximizing the substantial, multi-year growth opportunity for Cortrophin Gel by addressing the significant unmet medical need across indications." Nikhil Lalwani, President and CEO.
• "In 2026, we will continue momentum in our current priority therapeutic areas and also plan to expand our Rare Disease organization by mid-year, enabling us to capture the opportunity in acute gouty arthritis flares, an indication unique to ANI." Nikhil Lalwani, President and CEO.
• "Importantly, the ongoing execution across our Generics and Brands business will provide healthy cash generation to support our Rare Disease business. We look forward to driving long-term growth in 2026 and beyond to fulfill our purpose of Serving Patients, Improving Lives, while also creating durable value across the company." Nikhil Lalwani, President and CEO.

Industry Context

The ACTH market, which includes Cortrophin Gel and Acthar Gel, returned to double-digit growth in 2024 following the launch of Cortrophin Gel. The market is estimated to reach approximately $992 million in 2025, representing a 45% year-over-year increase. This indicates a growing demand and expanding market for ACTH therapies, with ANI's Cortrophin Gel being a significant driver of this expansion and capturing new prescribers. The company's strategic focus on rare diseases, particularly the expansion into acute gouty arthritis flares, aligns with a trend towards specialized, high-value therapeutic areas.

Comparison to Industry Standards

• The ACTH market, comprising Cortrophin Gel and Keenova Therapeutics' Acthar Gel, is estimated to reach ~$992 million in 2025, up 45% year-over-year. This growth is significantly driven by Cortrophin Gel's performance.
• Cortrophin Gel's 76% year-over-year growth in 2025 to $347.8 million demonstrates strong market penetration and competitive performance against Acthar Gel, which previously dominated the market.
• Approximately half of Cortrophin Gel prescribers were naive to the ACTH category before prescribing Cortrophin Gel, indicating successful market expansion rather than just market share capture from competitors.
• The company's plan to expand its Rare Disease organization by ~90 people for acute gouty arthritis flares positions it to capture a unique opportunity, as Cortrophin Gel is the only approved ACTH therapy for this indication.

Stakeholder Impact

• Shareholders/Investors: Positive impact due to strong financial performance, robust growth projections, and strategic expansion into high-growth rare disease markets, potentially leading to increased share value.
• Patients: Improved access to Cortrophin Gel for various autoimmune disorders and acute gouty arthritis flares, and ILUVIEN for ocular conditions, fulfilling the company's mission of "Serving Patients, Improving Lives."
• Employees: Expansion of the Rare Disease organization by ~90 people by mid-2026 indicates job creation and growth opportunities within the company.
• Suppliers/Manufacturing Partners: Continued demand for raw materials and manufacturing services due to increased production and new product launches, but also potential risks if single-source reliance causes disruptions.
• Creditors: Strong financial performance and cash generation could improve creditworthiness and ability to service debt, especially given the indebtedness from the Alimera acquisition.

Next Steps

• Nikhil Lalwani, President & CEO, will present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026.
• Report full year 2025 results during the fourth quarter 2025 earnings conference call in late February 2026.
• Continue momentum in current priority therapeutic areas for Cortrophin Gel (Nephrology, Neurology, Rheumatology, Pulmonology).
• Expand Rare Disease organization by mid-2026 with ~90 people to target acute gouty arthritis flares.
• Advance a Phase 4 clinical trial to support further scientific evidence and clinical data generation of Cortrophin Gel in patients with acute gouty arthritis flares.
• Continue to evaluate opportunities to enhance patient convenience for Cortrophin Gel.
• Leverage commercial and patient access initiatives to return ILUVIEN to growth.
• Maintain current cadence of 10 to 15 new product launches annually in the Generics business.
• Explore opportunities to expand the scope and scale of the Rare Disease business.
• Invest high single-digit percentage of Generics revenue into R&D to support the business.

Key Dates

Recommendation

The filing indicates exceptional performance in 2025, exceeding prior guidance, and provides very strong 2026 guidance with projected total revenues exceeding $1 billion and significant growth in the high-margin Rare Disease segment. The strategic expansion for Cortrophin Gel into acute gouty arthritis flares, backed by a substantial sales force increase and clinical trials, points to a robust multi-year growth trajectory. The Generics business continues to provide strong cash flow, supporting these growth initiatives. While preliminary results are unaudited, the consistent positive trend and clear strategic direction make this a compelling investment opportunity.

Keywords

ANI Pharmaceuticals, ANIP, Rare Disease, Cortrophin Gel, ILUVIEN, YUTIQ, Pharmaceuticals, Biopharmaceutical, Generics, EBITDA, Revenue, Financial Guidance, SEC Filing, 8-K, ACTH, Gouty Arthritis, Ophthalmology, Rheumatology, Nephrology, Neurology, Pulmonology, Drug Development, Commercialization